scholarly journals Patients and family caregivers report high treatment expectations during palliative chemotherapy: a longitudinal prospective study

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Tine Ikander ◽  
Stefan Starup Jeppesen ◽  
Olfred Hansen ◽  
Mette Raunkiær ◽  
Karin Brochstedt Dieperink
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Family Caregivers ◽  
Palliative Chemotherapy ◽  
Well Being ◽  
Small Cell ◽  
Small Cell Lung ◽  
Treatment Expectations ◽  
Thoracic Cancer

Abstract Background When discussing treatment options and future care, it is important to understand the expectations of patients and family caregivers related to palliative chemotherapy and to identify patterns in patients’ quality of life. The study aims were to evaluate differences in treatment expectations and quality of life between patients with thoracic cancer (non-small-cell lung cancer, small-cell lung cancer and mesothelioma) who were < 70 and ≥ 70 years of age and receiving palliative chemotherapy and to assess family caregivers’ treatment expectations. Methods A prospective longitudinal study included patients with thoracic cancer receiving outpatient palliative chemotherapy at a university hospital in Denmark and their family caregivers. Patients’ treatment expectations and quality of life were assessed three times during treatment with a survey of treatment expectations and the Functional Assessment of Cancer Therapy – General questionnaire. Family caregivers’ treatment expectations were assessed once. Results A total of 48 patients and 36 family caregivers participated between 2018 and 2019. No statistically significant age-related differences in treatment expectations and quality of life were identified. 28% of patients aged < 70 years and 7% of those aged ≥70 years expected a cure. Among family caregivers, 36% expected a cure. Across both age groups, mean total quality of life scores significantly decreased from 73.2 at first palliative chemotherapy cycle to 70.5 at third cycle (p = 0.02). No meaningful changes were found in quality of life within either age group. A subgroup analysis found no significant between-group differences in quality of life. Mean physical well-being score for all patients decreased from 20.3 at first cycle to 18.4 at third cycle (p = 0.03) and mean emotional well-being score decreased from 15.4 at first cycle to 14.6 at third cycle (p = 0.04). Conclusion This study emphasizes the importance of initiating conversations about treatment expectations and paying attention to expectations that may differ by the age of the patient and between patients and family caregivers. Addressing treatment expectations among patients and family caregivers and monitoring quality of life among patients is important in clinical practice.

QUALITY OF LIFE OF LATE STAGE NON-SMALL CELL LUNG CANCER PATIENTS

2016 ◽  
pp. 85-91
Author(s):  
Phuong Phung
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Late Stage ◽  
Palliative Chemotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Eortc Qlq

Background: Lung cancer is the most common malignancies and remains the leading cause of cancer-related deaths in Viet Nam. Majority of cases present initially at late stage. Palliative chemotherapy is the standard treatment for these situations to prolong survival and improve quality of life for the patient. Purpose: To appreciate quality of life in patients in late stage non-small cell lung cancer pre-post, during palliative chemotherapy and to determine the factors affecting on post-chemotherapy quality of life. Patients and Methods: A prospective, descriptive study, eligible patients included 65 late stage non-small cell lung cancer patients from Hue University Hospital from 1/2014 to 6/2016. The EORTC QLQ-C30 and Lung cancer Questionnaire EORTC QLQ-LC13 were used to assess quality of life. T-test was used to compare quality of life score at two assessed times. T-test, ANOVA, Mann Whitney, Kruskal Wallis were used to determine the correlation between 2 factors. Pearson and Spearman Coefficient were used to measure the strength of relationship between the factors. Results: The most effected age group was 54.4 ± 11.3. The global health scale before treatment was 47.3± 23.6, the functional scales as well as disease-related symptom scales improved clearly after the 2nd cycle (64.8 ± 16.0) and were relatively stable at the 4th cycle of chemotherapy (62.2 ± 19.3). Meanwhile, the toxicities including hair loss and peripheral neuropathy rose gradually after chemotherapy cycles. Age, occupation, nationality, religion, weight loss, PS, pathology, stage of disease, chemotherapy regimen, progressive disease, disease-related symptoms and treatment-related toxicities associated post-chemotherapy quality of life. Conclusions: This study showed that there were an improvement of quality of life after chemotherapy. Epidemiologic, clinical, treatment factors had effects on post-chemotherapy quality of life. Key words: lung cancer, quality of life, palliative chemotherapy

Nadaplatin or cisplatin combined with paclitaxol in treating non-small cell lung cancer: A randomized controlled study

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 7689-7689
Author(s):  
L. Chen ◽  
G. Xu ◽  
Z. Guan
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Treatment Effect ◽  
Side Effect ◽  
Response Rate ◽  
Well Being ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients

7689 Background: Nadaplatin is a 2nd generation platinum compound created in Japan. It also has been used in China for recent years and shown treatment effect in several kinds of cancer including lung cancer. However, no randomized clinical trial has been done compared with cisplatin when combined with paclitaxol in treating non-small cell lung cancer. This prospective clinical study is to investigate the treatment effect, long term survival, side effect and quality of life (QOL) of NSCLC patients treated with nadaplatin combined with paclitaxol controlled with cisplatin combined with paclitaxol. Methods: NSCLC patients with stage IIIB or IV were randomized into two groups: TN group- nadaplatin 30 mg/m2 d1–3, paclitaxol 175 mg/m2 d1, repeated every 4 weeks; TP group- DDP30 mg/m2 d1–3, paclitaxol 175 mg/m2 d1, repeated every 4 weeks. The treatment effect, 1 and 2 year survival and the side effect were observed. The functional assessment of cancer therapy-lung (FACT-L) was used to evaluate the quality of life (QOL). Results: Sixty patients were enrolled and 57 were assessable with 30 in TN group and 27 in TP group. The overall response rate were 43.3% vs 48.1% (P=0.716), and the disease control rate were 86.7% vs 88.8% in TN and TP group (P=0.799), respectively. The median survival time were 14.3 vs 13.0 months, and the 1 and 2 year survival were 62.5% vs 59.1%, 0% vs 5.8% in TN and TP group (P=0.839), respectively. Neutropenia and thrombocytopenia were similar in TN and TP group whereas more patients in TP group suffered from anemia (38.5% vs 17.5%, P=0.001), nausea and vomiting (68.0% vs 34.7% with grade 1 and 2, 14.6% vs 0.9% with grade 3 and 4, P=0.000), fatigue (35.9% vs 14.1% P=0.000) and peripheral neurotoxicity (50.0% vs 21.9%, calculated by case, p=0.023). In the FACT-L assessment, the relationship with doctor, the emotional well-being and the lung cancer related symptom were similarly improved in both TN and TP group whereas physical well-being was improved only in TN group. Conclusions: Nadaplatin combined with paclitaxol is an effective treatment regimen for NSCLC patients. When compared with similar regimen using cisplatin, the response rate and survival were similar; however, nadaplatin regimen shows superiority in some aspects of side effects and QOL. No significant financial relationships to disclose.

scholarly journals Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel

2015 ◽  
Vol 41 (2) ◽  
pp. 133-142 ◽  
Author(s):  
Camila Uanne Resende Avelino ◽  
Rafael Marques Cardoso ◽  
Suzana Sales de Aguiar ◽  
Mário Jorge Sobreira da Silva
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Lung Carcinoma ◽  
Palliative Chemotherapy ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Advanced Stage ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma

OBJECTIVE: Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. Most patients are diagnosed at an advanced stage, palliative chemotherapy therefore being the only treatment option. This study was aimed at evaluating the health-related quality of life (HRQoL) of advanced-stage NSCLC patients receiving palliative chemotherapy with carboplatin and paclitaxel. METHODS: This was a multiple case study of advanced-stage NSCLC outpatients receiving chemotherapy at a public hospital in Rio de Janeiro, Brazil. The European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire was used in conjunction with its supplemental lung cancer-specific module in order to assess HRQoL. RESULTS: Physical and cognitive functioning scale scores differed significantly among chemotherapy cycles, indicating improved and worsened HRQoL, respectively. The differences regarding the scores for pain, loss of appetite, chest pain, and arm/shoulder pain indicated improved HRQoL. CONCLUSIONS: Chemotherapy was found to improve certain aspects of HRQoL in patients with advanced-stage NSCLC.

scholarly journals Preliminary Efficacy and Safety of Reishi & Privet Formula on Quality of Life Among Non–Small Cell Lung Cancer Patients Undergoing Chemotherapy: A Randomized Placebo-Controlled Trial

2020 ◽  
Vol 19 ◽  
pp. 153473542094449
Author(s):  
Jie Liu ◽  
Jun J. Mao ◽  
Susan Qing Li ◽  
Hongsheng Lin
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Placebo Group ◽  
Cancer Patients ◽  
Well Being ◽  
Small Cell ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
To Receive

Background: Cancer patients often experience decreased quality of life during chemotherapy. This study aimed to determine the preliminary efficacy and safety of Reishi & Privet Formula (RPF) for maintaining quality of life among patients with non–small cell lung cancer (NSCLC) undergoing chemotherapy. Methods: We conducted a phase II randomized, double-blind, placebo-controlled clinical trial in China. Adults with NSCLC scheduled to receive chemotherapy were randomly assigned (3:1 ratio) to receive oral RPF (3.36 g/day) or placebo daily for 6 weeks. The main outcome was the Functional Assessment of Cancer Therapy–Lung (FACT-L). We evaluated RPF’s safety profile using the Common Terminology Criteria for Adverse Events and assessed changes in outcome measures from baseline to weeks 3 and 6 using a linear mixed effects model. Results: We enrolled 82 participants across 8 cancer centers in China. The median age was 59 years, 56 (68%) had advanced cancer. Compared with the placebo group, the RPF group had nonstatistically significant higher quality of life as measured by the FACT-L total score ( P = .086) over 2 cycles of chemotherapy. The RPF group was associated with a nonsignificant better general health ( P = .050) and emotional well-being ( P = .090) than the placebo group. Adverse events rates did not differ between groups. Conclusions: This study demonstrated preliminary safety and suggests a promising trend in RPF’s effect on maintaining quality of life and emotional well-being among NSCLC patients undergoing chemotherapy. Future adequately powered randomized-controlled trials are needed to verify the efficacy and safety of RPF in cancer patients undergoing chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document